多发性硬化症患者血清和脑脊液中可溶性Fas/APO 1的水平

Level of sFas/APO 1 in serum and cerebrospinal fluid in multiple sclerosis.

作者信息

Mahovic Darija, Petravic Damir, Petelin Zeljka, Zurak Niko, Horvat Gordana, Hajnsek Sanja

机构信息

Department of Neurology, Zagreb University Hospital Center, Kispaticeva 12, 10 000 Zagreb, Croatia.

出版信息

Clin Neurol Neurosurg. 2004 Jun;106(3):230-2. doi: 10.1016/j.clineuro.2004.02.020.

DOI:10.1016/j.clineuro.2004.02.020

PMID:15177773

Abstract

The aim of the study was to measure sFas/APO 1 serum and cerebrospinal fluid (CSF) levels in patients with relapsing-remitting multiple sclerosis (MS) during relapses, as an index of inhibition of apoptosis of activated lymphocytes in eight patients with clinically definite multiple sclerosis, and 12 healthy controls. The level of serum and CSF sFas/APO 1 was determined by commercially available enzyme-linked immunosorbent assay (ELISA) kits. No significant differences were detected in the sFas/APO 1 serum level between patients and controls, but the levels in CSF was lower in the former. Our results suggest the possibility of Fas mediated apoptosis as a contributing factor in the pathogenesis of multiple sclerosis.

摘要

本研究旨在测定复发缓解型多发性硬化症（MS）患者复发期血清和脑脊液（CSF）中可溶性Fas/APO-1水平，以此作为8例临床确诊的多发性硬化症患者及12名健康对照者中活化淋巴细胞凋亡抑制指标。血清和脑脊液中sFas/APO-1水平采用市售酶联免疫吸附测定（ELISA）试剂盒进行测定。患者与对照者的血清sFas/APO-1水平未检测到显著差异，但前者脑脊液中的水平较低。我们的结果提示Fas介导的凋亡有可能是多发性硬化症发病机制中的一个促成因素。